CN101754758B - 一种用于治疗阿尔茨海默氏症的包含喹诺酮衍生物和多奈哌齐的药物 - Google Patents
一种用于治疗阿尔茨海默氏症的包含喹诺酮衍生物和多奈哌齐的药物 Download PDFInfo
- Publication number
- CN101754758B CN101754758B CN2008800167568A CN200880016756A CN101754758B CN 101754758 B CN101754758 B CN 101754758B CN 2008800167568 A CN2008800167568 A CN 2008800167568A CN 200880016756 A CN200880016756 A CN 200880016756A CN 101754758 B CN101754758 B CN 101754758B
- Authority
- CN
- China
- Prior art keywords
- donepezil
- salt
- disease
- carbostyril derivative
- alzheimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 29
- 229960003530 donepezil Drugs 0.000 title claims abstract description 22
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title abstract description 35
- 150000003839 salts Chemical class 0.000 claims abstract description 35
- 229960003135 donepezil hydrochloride Drugs 0.000 claims description 21
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 9
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 7
- BUWPZNOVIHAWHW-UHFFFAOYSA-N 2,3-dihydro-1h-quinolin-4-one Chemical compound C1=CC=C2C(=O)CCNC2=C1 BUWPZNOVIHAWHW-UHFFFAOYSA-N 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 229960004588 cilostazol Drugs 0.000 description 8
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 125000001118 alkylidene group Chemical group 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- -1 salt compound Chemical class 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 238000002638 palliative care Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 208000024571 Pick disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010036933 Presenilin-1 Proteins 0.000 description 1
- 102100022033 Presenilin-1 Human genes 0.000 description 1
- 108010036908 Presenilin-2 Proteins 0.000 description 1
- 102100022036 Presenilin-2 Human genes 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000021018 autosomal dominant inheritance Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- ZPFKRQXYKULZKP-UHFFFAOYSA-N butylidene Chemical group [CH2+]CC[CH-] ZPFKRQXYKULZKP-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002743 euphoric effect Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- RFPMGSKVEAUNMZ-UHFFFAOYSA-N pentylidene Chemical group [CH2+]CCC[CH-] RFPMGSKVEAUNMZ-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种用于治疗阿尔茨海默氏症的药物，其含有下列通式的喹诺酮衍生物或其盐和多奈哌齐或其盐作为活性成分，其中A为低级亚烷基，R为环烷基，在喹诺酮骨架的3-和4-位之间的键是单键或双键。
Description
技术领域
本发明涉及一种用于治疗阿尔茨海默氏症的药物，特别是含有下列通式的喹诺酮衍生物或其盐和多奈哌齐或其盐作为活性成分的用于治疗阿尔茨海默氏症的药物：
其中A为低级亚烷基，R为环烷基，喹诺酮骨架的3-和4-位之间的键是单键或双键。
背景技术
式(1)的喹诺酮衍生物或其盐和其制备方法被公开于JP-63-20235-B和JP-55-35019-A中。并且已知喹诺酮衍生物(1)具有血小板聚集抑制作用、磷酸二酯酶(PDE)抑制作用、抗溃疡、降血压作用和抗炎作用，可以用作抗血栓形成药物、用于改善脑循环的药物、抗炎药物、抗溃疡药物、抗高血压药物、抗哮喘药物、磷酸二酯酶抑制剂等。此外，已知这类化合物也可用作治疗过敏性疾病的药物(JP-5-320050-A)。还已知喹诺酮衍生物(1)是用于治疗阿尔茨海默氏症的药物(JP-2006-518732-A)。
在日本，患有痴呆的患者数估计为1,890,000人，2005年其患病率估计为7.6％，并且患病人数和患病率都会随着社会老龄化的进展而日益增长。可以理解患有阿尔茨海默氏症(AD)的患者数占痴呆患者总数的一半以上。
大部分的AD被认为是散发病例，但是包括大约10％的家族性AD，由于基因例如淀粉样前体蛋白基因、早老素-1和早老素-2的错义突变，其发作伴有常染色体显性遗传。特别地，女性更易罹患AD。AD最重要的危险因素是衰老。AD的患病率随年龄增长而增加，因此大部分的AD是迟发性AD，其在65岁时或65岁后发作。AD患者会表现出不同的病理学状态，取决于神经递质例如乙酰胆碱的紊乱、大脑内淀粉样β蛋白蓄积造成的老年斑的形成、含有磷酸化的π和其他物质的不正常纤丝的神经元内蓄积、通过脱落神经细胞造成的大脑严重萎缩等。AD的核心症状包括记忆损伤、失语症、认知损伤、执行功能紊乱和相关症状；它们中的很多都是精神愉快的。然而，一些AD的症状表现出相反的情况，例如缺乏动力、抑郁、坏情绪、从发作开始的坏脾气。
盐酸多奈哌齐(商品名：安理申)在临床实践中被广泛应用于治疗AD的主要症状(JP-2578475-B)。对于相关症状，例如失眠、坏脾气和妄想症，盐酸多奈哌齐也可用作姑息治疗(Japanese Journal of Psychiatric Treatment，第21卷，增刊，第302-305页，2006年10月15日，Tsuneyoshi Ohta，Heii Arai)。但是，盐酸多奈哌齐姑息治疗的作用在长期使用时容易下降。因此，由于该药物需要被长期给药，盐酸多奈哌齐也具有难以持续和充分抑制病情发展的问题。
发明的公开
如上所述，盐酸多奈哌齐(商品名：
)已经被广泛地用作治疗阿尔茨海默氏症的药物，但是，仍然需要开发治疗阿尔茨海默氏症的更有效的药物，其能够抑制在长期给药时盐酸多奈哌齐治疗效果的降低。
本发明人已经深入研究了一种新的用于治疗阿尔茨海默氏症的药物，并且发现了上述式(1)的喹诺酮衍生物，特别是6-[4-(1-环己基-1H-四唑-5-基)丁氧基]-3，4-二氢喹诺酮(西洛他唑)或其盐与多奈哌齐或其盐的组合或药物组合，对于治疗阿尔茨海默氏症表现出极好的协同作用，从而完成了本发明。特别地，本发明人已发现本发明的组合表现出极好的改善由于盐酸多奈哌齐长期给药而降低的盐酸多奈哌齐活性的作用。此外，本发明的组合或药物组合表现出快速起效和低毒性，因此它可以被长期给药。从安全性的角度考虑，本发明也是治疗阿尔茨海默氏症的有用药物。
本发明提供一种用于治疗阿尔茨海默氏症的药物，其含有下列通式的喹诺酮衍生物或其盐和多奈哌齐或其盐作为活性成分：
其中A为低级亚烷基，R为环烷基，在喹诺酮骨架的3-和4-位之间的键是单键或双键。
本发明还提供一种用于治疗阿尔茨海默氏症的药物，含有6-[4-(1-环己基-1H-四唑-5-基)丁氧基]-3，4-二氢喹诺酮(西洛他唑)或其盐与多奈哌齐或其盐作为活性成分。
本发明还提供一种用于治疗阿尔茨海默氏症的药物，含有喹诺酮衍生物(1)和盐酸多奈哌齐作为活性成分。
本发明还提供一种含有上述活性成分的用于治疗阿尔茨海默氏症的组合物。
本发明还提供喹诺酮衍生物(1)或其盐和多奈哌齐或其盐在制备用于治疗阿尔茨海默氏症的药物中的应用。
本发明还提供用于治疗阿尔茨海默氏症的方法，包括给予需要这种治疗的患者有效量的喹诺酮衍生物(1)或其盐和多奈哌齐或其盐。
根据本发明，喹诺酮衍生物(1)，特别是6-[4-(1-环己基-1H-四唑-5-基)丁氧基]-3，4-二氢喹诺酮或其盐与多奈哌齐的组合对于阿尔茨海默氏症表现出有效的治疗和预防作用。
附图简述
图1表示以组合形式一起使用盐酸多奈哌齐和西洛他唑对阿尔茨海默氏症的治疗效果。
实施本发明的最佳方式
包含在药物组合或以与多奈哌齐或其盐组合方式使用的喹诺酮衍生物是下列通式的四唑烷氧基二氢喹诺酮衍生物或其盐：
其中A为低级亚烷基，R为环烷基，在喹诺酮骨架的3-和4-位之间的键是单键或双键。
在上述式(1)中，环烷基包括C3-C8环烷基，例如环丙基、环丁基、环戊基、环己基、环庚基和环辛基。优选的环烷基是环己基。低级亚烷基包括C1-C6亚烷基，例如亚甲基、亚乙基、亚丙基、四亚甲基、亚丁基和亚戊基，其中优选的是四亚甲基。
优选的喹诺酮衍生物是6-[4-(1-环己基-1H-四唑-5-基)丁氧基]-3，4-二氢喹诺酮，它已经作为抗血小板药物以商品名西洛他唑被投入了市场。
可以通过用药学上可接受的酸处理将喹诺酮衍生物(1)容易地转化为它的盐。所述的酸包括，如，无机酸例如盐酸、硫酸、磷酸和氢溴酸；有机酸例如草酸、马来酸、富马酸、苹果酸、酒石酸、柠檬酸和苯甲酸。
这些喹诺酮衍生物(1)及其盐和其制备方法被公开于JP-55-35019-A中(与美国专利4,277,479相关)。
另一活性成分是多奈哌齐，其化学名是1-苯甲基-4-[(5，6-二甲氧基茚满-1-酮)-2-基]甲基哌嗪。其盐酸盐已经作为治疗阿尔茨海默氏症的药物被投入了市场(盐酸多奈哌齐，商品名：
)。该化合物被公开于JP-2578475-B中。可以使用药学上可接受的酸将本发明的1-苯甲基-4-[(5，6-二甲氧基茚满-1-酮)-2-基]甲基哌嗪容易地转化为其盐的形式。所述的酸包括，如，无机酸例如盐酸、硫酸、磷酸和氢溴酸；有机酸例如草酸、马来酸、富马酸、苹果酸、酒石酸、柠檬酸和苯甲酸。其中，其盐酸盐，盐酸多奈哌齐是优选的。
这些活性成分，喹诺酮衍生物(1)或其盐和多奈哌齐或其盐可以同时地或在不同的时间被一起或分开给药。这些成分通常可以被用于常规的药物制剂中。然后，这些成分可以被制成单一剂型或分开的剂型。
含有本发明的喹诺酮衍生物(1)或其盐和多奈哌齐或其盐的药物适用于包括阿尔茨海默氏症在内的普通痴呆病症。因此，本发明药物的应用包括认知损伤，例如阿尔茨海默型痴呆、老年性痴呆和早发性痴呆，以及亨廷顿氏症、皮克病、迟发性运动障碍等。
这些活性成分的剂量不限于特定的范围。喹诺酮衍生物(1)或其盐可以以每个成年人(50kg体重)50-200mg/天的量被使用，每天一次或者每天两次到数次被给药。多奈哌齐可以以每个成年人(50kg体重)大约0.1-300mg/天，优选大约1-10mg/天的量被使用，通常每天被给药一到四次。当这些组分被制成单一剂型时，它们以每1重量份的喹诺酮衍生物(1)或其盐0.025-1.0重量份的多奈哌齐的比例被混合。并且，该药物组合可以包括占制剂的0.1-70％(w/w)的这些成分的总和，但不限于此。
用于本发明的药物组合或组合的每种剂型包括，例如，JP-10-175864-A中例举的剂型，和一般的口服固体剂型，如片剂和胶囊，口服液体剂型，如糖浆和酏剂，非肠道剂型，如注射剂和吸入剂。
本发明的制剂，例如片剂、胶囊、用于口服给药的液体可以通过常规方法被制备。片剂可以通过将活性成分和常规的药用载体，如明胶、淀粉、乳糖、硬脂酸镁、滑石粉、阿拉伯胶等混合来制备。胶囊可以通过将活性成分和惰性药学赋形剂或稀释剂混合并且用混合物填装硬胶囊或软胶囊来制备。口服液体制剂，例如糖浆和酏剂可以通过将活性成分和甜味剂(如蔗糖)、防腐剂(如对羟基苯甲酸甲酯、对羟基苯甲酸丙酯)、着色剂、调味剂等混合来制备。用于非肠道给药的制剂也可以通过常规方法被制备，例如，将本发明的活性成分溶解在无菌水性载体中，优选水或盐水溶液中。优选的适用于非肠道给药的液体制剂可以通过将每日剂量的上述活性成分溶解在水中和有机溶剂中并进一步溶解在分子量为300到5000的聚乙二醇中而被制备，其中优选掺入润滑剂，例如羧甲基纤维素钠、甲基纤维素、聚乙烯吡咯烷酮和聚乙烯醇。优选地，上述液体制剂可以进一步含有消毒剂(例如，苯甲醇、苯酚、硫柳汞)、杀真菌剂，以及进一步任选地包含等渗剂(如蔗糖、氯化钠)、局部麻醉剂、稳定剂、缓冲剂等。为了保持稳定，用于非肠道给药的制剂可以被放入胶囊中，然后通过常规的冷冻干燥技术除去水性介质。在使用时可以通过将该制剂溶于水性介质而将其复原成液体制剂。可以通过常规方法制备吸入剂。即，可以通过将活性化合物变成粉末或液体状态，使其混合于供吸入剂用的推进剂和/或载体中，和将该混合物装入合适的喷雾器中来制备吸入剂。通常，当活性化合物是粉末时，可以使用机械式粉末喷雾器，当化合物是液体时，可以使用喷雾器例如雾化器。此外，在必要时吸入剂还可任选地含有已经使用的表面活性剂、油、调味剂、环糊精或其衍生物。
上述添加剂的实例、其制备方法或其他事情包括，但不限于JP-10-175864-A公开的内容。
实施例
两名患有阿尔茨海默氏症的女性(一名63岁，另一名52岁)已经分别以5mg/天的剂量被给药盐酸多奈哌齐
12个月和9个月。在给药期间，对这些女性进行细微精神状态检查(MMSE)(Journal of psychiatric research.1975年11月；12(3)：189-98)，结果如表1和图1中所示。在实验开始的时候(0月)，以100mg/天的剂量以与盐酸多奈哌齐的组合形式开始给药西洛他唑。那时，之前已经降低的MMSE得分迅速被提高。根据上述结果，发现以与盐酸多奈哌齐组合形式给药西洛他唑可以恢复由于盐酸多奈哌齐长期给药而倾向于降低的盐酸多奈哌齐的作用。并且还发现盐酸多奈哌齐和西洛他唑的组合对痴呆例如阿尔茨海默氏症能够提供强效的治疗作用。
表1
M(s)表示“月”。
组合中西洛他唑的给药开始于0月。
Claims (6)
1.一种用于治疗阿尔茨海默氏症的药物，含有6-[4-(1-环己基-1H-四唑-5-基)丁氧基]-3，4-二氢喹诺酮或其盐和多奈哌齐或其盐作为活性成分。
2.权利要求1的药物，其中多奈哌齐的盐是盐酸多奈哌齐。
3.6-[4-(1-环己基-1H-四唑-5-基)丁氧基]-3，4-二氢喹诺酮或其盐和多奈哌齐或其盐在制备用于治疗阿尔茨海默氏症的药物中的应用。
4.权利要求3的应用，其中所述的多奈哌齐的盐是盐酸多奈哌齐。
5.一种用于治疗阿尔茨海默氏症的组合物，包括有效量的6-[4-(1-环己基-1H-四唑-5-基)丁氧基]-3，4-二氢喹诺酮或其盐和多奈哌齐或其盐。
6.权利要求5的组合物，其中所述的多奈哌齐的盐是盐酸多奈哌齐。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007135367 | 2007-05-22 | ||
| JP135367/2007 | 2007-05-22 | ||
| PCT/JP2008/059763 WO2008143361A1 (en) | 2007-05-22 | 2008-05-21 | A medicament comprising a carbostyril derivative and donepezil for treating alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101754758A CN101754758A (zh) | 2010-06-23 |
| CN101754758B true CN101754758B (zh) | 2012-10-24 |
Family
ID=39636992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008800167568A Expired - Fee Related CN101754758B (zh) | 2007-05-22 | 2008-05-21 | 一种用于治疗阿尔茨海默氏症的包含喹诺酮衍生物和多奈哌齐的药物 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20100298375A1 (zh) |
| EP (2) | EP2937085B1 (zh) |
| JP (1) | JP5153870B2 (zh) |
| KR (1) | KR101441725B1 (zh) |
| CN (1) | CN101754758B (zh) |
| AR (1) | AR066664A1 (zh) |
| AU (1) | AU2008253977B2 (zh) |
| BR (1) | BRPI0811919A2 (zh) |
| CA (1) | CA2687289C (zh) |
| CO (1) | CO6251249A2 (zh) |
| CY (1) | CY1116683T1 (zh) |
| DK (1) | DK2157973T3 (zh) |
| ES (1) | ES2545959T3 (zh) |
| HK (2) | HK1140422A1 (zh) |
| HR (1) | HRP20150843T1 (zh) |
| HU (1) | HUE025902T2 (zh) |
| IL (1) | IL202053A (zh) |
| MX (1) | MX2009012583A (zh) |
| MY (1) | MY146407A (zh) |
| NZ (1) | NZ581099A (zh) |
| PL (1) | PL2157973T3 (zh) |
| PT (1) | PT2157973E (zh) |
| RU (1) | RU2469723C2 (zh) |
| SI (1) | SI2157973T1 (zh) |
| TW (2) | TWI489983B (zh) |
| UA (1) | UA96633C2 (zh) |
| WO (1) | WO2008143361A1 (zh) |
| ZA (1) | ZA200908202B (zh) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2135607A1 (en) | 2008-06-18 | 2009-12-23 | Pharnext | Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders |
| EP2322163A1 (en) * | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
| US9387206B2 (en) | 2009-11-03 | 2016-07-12 | Pharnext | Therapeutic approaches for treating Alzheimer's disease |
| US9248111B2 (en) | 2011-03-01 | 2016-02-02 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| US9241933B2 (en) | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
| US10010515B2 (en) | 2011-03-01 | 2018-07-03 | Pharnext | Therapeutic approaches for treating Parkinson's disease |
| WO2012117075A2 (en) | 2011-03-01 | 2012-09-07 | Pharnext | Treatment of cerebral ischemia |
| SG11201408323RA (en) * | 2012-06-15 | 2015-01-29 | Found Biomedical Res & Innov | Prophylactic and/or therapeutic agent for mild cognitive impairment |
| WO2015100255A2 (en) * | 2013-12-23 | 2015-07-02 | Holaday John W | Disposable container for air hydration |
| JP6872201B2 (ja) | 2016-05-19 | 2021-05-19 | 国立研究開発法人国立循環器病研究センター | 認知症の予防及び／又は治療のための薬剤 |
| WO2018215478A1 (en) | 2017-05-24 | 2018-11-29 | H. Lundbeck A/S | Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles |
| CN107602523B (zh) * | 2017-09-11 | 2020-08-18 | 安徽中医药大学 | 京尼平类似物、制备方法及其应用 |
| PL237739B1 (pl) | 2018-06-06 | 2021-05-17 | Univ Gdanski | Genisteina do zastosowania do leczenia choroby Alzheimera |
| NL2024431B1 (en) | 2019-12-11 | 2021-09-07 | Sulfateq Bv | Compounds for treatment of alzheimer’s disease |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004075897A1 (en) * | 2003-02-25 | 2004-09-10 | Otsuka Pharmaceutical Co., Ltd. | Pten inhibitor or maxi-k channels opener |
| CN1607952A (zh) * | 2001-12-27 | 2005-04-20 | 大塚制药株式会社 | 包含多官能磷酸二酯酶抑制剂和腺苷吸收抑制剂的药物组合物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5535019A (en) * | 1978-09-01 | 1980-03-11 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| JPS5649378A (en) | 1979-08-25 | 1981-05-02 | Otsuka Pharmaceut Co Ltd | Tetrazolylalkoxycarbostyril derivative |
| FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| JP2574099B2 (ja) | 1992-05-21 | 1997-01-22 | 大塚製薬株式会社 | アレルギー疾患治療剤 |
| JPH10175864A (ja) | 1996-12-16 | 1998-06-30 | Otsuka Pharmaceut Co Ltd | 慢性閉塞性肺疾患治療剤 |
| US6322525B1 (en) * | 1997-08-28 | 2001-11-27 | Visco Technologies, Inc. | Method of analyzing data from a circulating blood viscometer for determining absolute and effective blood viscosity |
| US6322524B1 (en) * | 1997-08-28 | 2001-11-27 | Visco Technologies, Inc. | Dual riser/single capillary viscometer |
| US6019735A (en) * | 1997-08-28 | 2000-02-01 | Visco Technologies, Inc. | Viscosity measuring apparatus and method of use |
| US6428488B1 (en) * | 1997-08-28 | 2002-08-06 | Kenneth Kensey | Dual riser/dual capillary viscometer for newtonian and non-newtonian fluids |
| US6252081B1 (en) * | 1998-01-16 | 2001-06-26 | Eisai Co., Ltd. | Process for production of donepezil derivative |
| US6187790B1 (en) * | 1999-03-04 | 2001-02-13 | Neal R. Cutler | Use of cilostazol for treatment of sexual dysfunction |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6484565B2 (en) * | 1999-11-12 | 2002-11-26 | Drexel University | Single riser/single capillary viscometer using mass detection or column height detection |
| US6458804B1 (en) * | 2001-01-26 | 2002-10-01 | R.T. Alamo Venturesi, Llc | Methods for the treatment of central nervous system disorders in certain patient groups |
| IL150509A (en) * | 2002-07-01 | 2007-07-04 | Joseph Kaspi | Pharmaceutical preparations containing donafazil hydrochloride |
| US6743806B2 (en) * | 2002-10-23 | 2004-06-01 | Otsuka Pharmaceutical Company, Limited | Active oxygen scavenger |
| FR2848452B1 (fr) * | 2002-12-12 | 2007-04-06 | Aventis Pharma Sa | Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer |
| JP2004189706A (ja) * | 2002-12-13 | 2004-07-08 | Eisai Co Ltd | 高度アルツハイマー型痴呆治療剤 |
-
2008
- 2008-05-21 TW TW102147146A patent/TWI489983B/zh not_active IP Right Cessation
- 2008-05-21 MX MX2009012583A patent/MX2009012583A/es active IP Right Grant
- 2008-05-21 SI SI200831493T patent/SI2157973T1/sl unknown
- 2008-05-21 UA UAA200913247A patent/UA96633C2/uk unknown
- 2008-05-21 EP EP15164200.6A patent/EP2937085B1/en active Active
- 2008-05-21 NZ NZ581099A patent/NZ581099A/en not_active IP Right Cessation
- 2008-05-21 PL PL08764779T patent/PL2157973T3/pl unknown
- 2008-05-21 MY MYPI20094815A patent/MY146407A/en unknown
- 2008-05-21 PT PT87647798T patent/PT2157973E/pt unknown
- 2008-05-21 WO PCT/JP2008/059763 patent/WO2008143361A1/en active Application Filing
- 2008-05-21 EP EP08764779.8A patent/EP2157973B1/en not_active Not-in-force
- 2008-05-21 CN CN2008800167568A patent/CN101754758B/zh not_active Expired - Fee Related
- 2008-05-21 JP JP2010509026A patent/JP5153870B2/ja not_active Expired - Fee Related
- 2008-05-21 BR BRPI0811919-8A2A patent/BRPI0811919A2/pt not_active IP Right Cessation
- 2008-05-21 CA CA2687289A patent/CA2687289C/en not_active Expired - Fee Related
- 2008-05-21 DK DK08764779.8T patent/DK2157973T3/en active
- 2008-05-21 US US12/599,962 patent/US20100298375A1/en not_active Abandoned
- 2008-05-21 AU AU2008253977A patent/AU2008253977B2/en not_active Ceased
- 2008-05-21 RU RU2009147456/15A patent/RU2469723C2/ru not_active IP Right Cessation
- 2008-05-21 TW TW097118634A patent/TWI423802B/zh not_active IP Right Cessation
- 2008-05-21 KR KR1020097026651A patent/KR101441725B1/ko active IP Right Grant
- 2008-05-21 HU HUE08764779A patent/HUE025902T2/en unknown
- 2008-05-21 AR ARP080102154A patent/AR066664A1/es unknown
- 2008-05-21 ES ES08764779.8T patent/ES2545959T3/es active Active
-
2009
- 2009-11-11 IL IL202053A patent/IL202053A/en not_active IP Right Cessation
- 2009-11-20 ZA ZA200908202A patent/ZA200908202B/xx unknown
- 2009-12-21 CO CO09145995A patent/CO6251249A2/es active IP Right Grant
-
2010
- 2010-07-13 HK HK10106804.1A patent/HK1140422A1/zh not_active IP Right Cessation
-
2015
- 2015-08-07 HR HRP20150843TT patent/HRP20150843T1/hr unknown
- 2015-09-14 CY CY20151100797T patent/CY1116683T1/el unknown
-
2016
- 2016-03-23 HK HK16103366.2A patent/HK1215384A1/zh not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1607952A (zh) * | 2001-12-27 | 2005-04-20 | 大塚制药株式会社 | 包含多官能磷酸二酯酶抑制剂和腺苷吸收抑制剂的药物组合物 |
| WO2004075897A1 (en) * | 2003-02-25 | 2004-09-10 | Otsuka Pharmaceutical Co., Ltd. | Pten inhibitor or maxi-k channels opener |
Non-Patent Citations (1)
| Title |
|---|
| Jeong Hyun Lee et al..Concurrent administration of cilostazol with donepezil effectively improves cognitive dysfunction with increased neuroprotection after chronic cerebral hypoperfusion in rats.《Brain Research》.2007,第1185卷第246-255页. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101754758B (zh) | 一种用于治疗阿尔茨海默氏症的包含喹诺酮衍生物和多奈哌齐的药物 | |
| US6262081B1 (en) | Composition for and method of treating neurological disorders | |
| EP1675591B1 (en) | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor | |
| US20100160372A1 (en) | Treatment of proteinopathies using a farnesyl transferase inhibitor | |
| JP5558348B2 (ja) | シロスタゾールを含むカルボスチリル誘導体の脂肪肝治療剤 | |
| JP2004536844A (ja) | 哺乳類におけるコリン性機能調節の医薬組成物及び方法 | |
| JP2006519225A5 (zh) | ||
| TW200848041A (en) | A medicament for treating schizophrenia comprising cilostazol | |
| AU2015258814B2 (en) | Clearance of amyloid ss | |
| EP1667769A2 (de) | Verwendung von galanthamin und seinen derivaten zum herstellen von arzneimitteln | |
| KR101442874B1 (ko) | 만성 폐색성 폐질환 치료제 | |
| JP2019524682A (ja) | 抗うつ作用の速い発現のためのボルチオキセチン投与計画 | |
| EP0324348A2 (de) | Piperidincarboxamid-Derivate zur Behandlung von Bradycardien und Bradyarrhythmien | |
| AU2001247867A1 (en) | Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121024 Termination date: 20210521 |